Scancell Fast-Tracks Melanoma Study with NHS Partnership

NHS Partnership for SCOPE Study

• 🚀 Scancell has partnered with the NHS Cancer Vaccine Launchpad to accelerate patient recruitment for its SCOPE study.
• ✅ This collaboration is seen as a positive endorsement for Scancell and its experimental iSCIB1+ therapy.
• 💡 The partnership enables faster access for patients in the United Kingdom to the iSCIB1+ therapy for advanced melanoma.
• 🇬🇧 Scancell is the first UK company and iSCIB1+ is the first DNA cancer vaccine to be available through this NHS platform.

iSCIB1+ DNA Cancer Vaccine

• 🧬 The iSCIB1+ DNA vaccine aims to generate long-term immune control in tumors, improving duration of response and progression-free survival.
• 🤝 It is administered on top of standard checkpoint therapies to synergistically boost response rates and prolong efficacy.
• 🎯 This approach seeks to benefit more melanoma patients, especially since checkpoint therapies alone are effective for only about half, with often short-lived responses.

Clinical Development Timelines

• 📊 Data readouts for the iSCIB1+ cohorts in the SCOPE study are anticipated in mid-2025 and late 2025.
• 🔬 The goal for 2025 is to identify patient responders, optimal therapy delivery, and immunization methods to inform the next development phase.
• 🌱 The next phase of development for iSCIB1+ is planned to commence in the second half of 2026.

Broader Pipeline and Strategic Focus

• 🧪 Scancell's pipeline also includes the Modi-1 peptide vaccine, which is in Phase 2 for multiple tumor types, with data expected in H2 2025.
• 🔬 The company is also developing its GlyMab antibody platform, including the SC134 program for small cell lung cancer.
• 🔑 CEO Phillip L’Huillier's priorities include meeting development timelines, fostering strategic partnerships, and preparing the organization for future growth.